EverSource Wealth Advisors LLC Trims Stock Position in Amgen Inc. $AMGN

EverSource Wealth Advisors LLC lowered its position in Amgen Inc. (NASDAQ:AMGN) by 13.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 19,132 shares of the medical research company’s stock after selling 2,936 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Amgen were worth $5,399,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in AMGN. Brighton Jones LLC increased its holdings in shares of Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after buying an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC lifted its holdings in shares of Amgen by 10.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after acquiring an additional 114 shares during the last quarter. Schnieders Capital Management LLC. grew its position in Amgen by 29.3% in the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after acquiring an additional 5,853 shares in the last quarter. MQS Management LLC bought a new position in Amgen in the second quarter valued at $202,000. Finally, Oppenheimer Asset Management Inc. raised its position in Amgen by 23.9% during the second quarter. Oppenheimer Asset Management Inc. now owns 1,098 shares of the medical research company’s stock valued at $307,000 after purchasing an additional 212 shares in the last quarter. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

NASDAQ:AMGN opened at $379.42 on Tuesday. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The firm’s fifty day simple moving average is $344.29 and its 200 day simple moving average is $317.21. The stock has a market cap of $204.53 billion, a P/E ratio of 26.66, a price-to-earnings-growth ratio of 3.71 and a beta of 0.46. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $385.12.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, topping the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same period last year, the business posted $5.31 earnings per share. Amgen’s quarterly revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. As a group, research analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be paid a $2.52 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s payout ratio is currently 70.84%.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the company. Wall Street Zen cut Amgen from a “buy” rating to a “hold” rating in a report on Saturday. Argus increased their price target on shares of Amgen from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Friday, February 6th. Citigroup lifted their price target on shares of Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 4th. Rothschild & Co Redburn boosted their price objective on shares of Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a report on Wednesday, February 18th. Finally, Mizuho upped their price objective on shares of Amgen from $280.00 to $295.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $351.76.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.